Recombinant Human TNF-α  
Catalog Number: 210-TA

**DESCRIPTION**

**Source**  
*E. coli*-derived  
Val77-Leu233, with and without an N-terminal Met  
Accession # P01375  

**N-terminal Sequence Analysis**  
Met & Val77  

**Predicted Molecular Mass**  
17.5 kDa  

**SPECIFICATIONS**

**SDS-PAGE**  
17 kDa, reducing conditions  

**Activity**  
The specific activity of Recombinant Human TNF-α is approximately 7.6 x 10⁴ IU/μg, which is calibrated against human TNF-α WHO International Standard (NIBSC code: 88/786).  

**Endotoxin Level**  
<0.10 EU per 1 μg of the protein by the LAL method.  

**Purity**  
>97%, by SDS-PAGE under reducing conditions and visualized by silver stain.  

**Formulation**  
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.  

**PREPARATION AND STORAGE**

**Reconstitution**  
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.  

**Shipping**  
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.  

**Stability & Storage**  
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.  
- 12 months from date of receipt, -20 to -70 °C as supplied.  
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.  
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.  

**DATA**

**Bioactivity**  
Recombinant Human TNF-α (Catalog # 210-TA) induces cytotoxicity in the L-929 mouse fibroblast cell line in the presence of the metabolic inhibitor actinomycin D. The ED₅₀ for this effect is 25-100 pg/mL.  

**SDS-PAGE**  
1 μg lane of Recombinant Human TNF-α was resolved by SDS-PAGE with silver staining, under reducing (R) conditions, showing a band at 17 kDa.
Tumor necrosis factor alpha (TNF-α), also known as cachectin and TNFSF2, is the prototypic ligand of the TNF superfamily. It is a pleiotropic molecule that plays a central role in inflammation, immune system development, apoptosis, and lipid metabolism (1, 2). Human TNF-α consists of a 35 amino acid (aa) cytoplasmic domain, a 21 aa transmembrane segment, and a 177 aa extracellular domain (ECD) (3). Within the ECD, human TNF-α shares 97% aa sequence identity with rhesus and 71%-92% with bovine, canine, cotton rat, equine, feline, mouse, porcine, and rat TNF-α. TNF-α is produced by a wide variety of immune, epithelial, endothelial, and tumor cells (1, 2). TNF-α is assembled intracellularly to form a noncovalently linked homotrimer which is expressed on the cell surface (4). Cell surface TNF-α can induce the lysis of neighboring tumor cells and virus infected cells, and it can generate its own downstream cell signaling following ligation by soluble TNFR I (2, 5). Shedding of membrane bound TNF-α by TACE/ADAM17 releases the bioactive cytokine, a 55 kDa soluble trimer of the TNF-α extracellular domain (6-8). TNF-α binds the ubiquitous 55-60 kDa TNF RI (9, 10) and the hematopoietic cell-restricted 80 kDa TNF RII (11, 12), both of which are also expressed as homotrimers (1, 2, 13). Both type I and type II receptors bind TNF-α with comparable affinity (14), although only TNF RI contains a cytoplasmic death domain which triggers the activation of apoptosis. Soluble forms of both types of receptors are released and can neutralize the biological activity of TNF-α (15).

References: